Trilantic Capital Partners Europe private equity firm is to buy a 90% stake in Doppel Farmaceutici, a leading Italian company active in pharmaceutical research, development, formulation, manufacturing and packaging, in outsourcing only.
Sellers are some private shareholders with Pierluigi Busca and Paolo Lanfranchi among them. Mr. Lanfranchi, Doppel’s founder and ceo, will keep a 10% stake in the company, and will be appointed chairman while  Giuseppe Cassisi will be appointed as the new ceo.
Founded in 1994, Doppel counts 460 employees in two productive plants in Northern Italy (Cortemaggiore and Rozzano). The company manufactures and packages mainly: capsules, tablets, coated tablets, high potency tablets, pharmaceutical granules, creams, gels, lotions, suppositories,  drops, syrups, oral solutions, sterile filling injection vials.
Since 2003, Doppel also has been working also with a food division dedicated to effervescent alimentary granules manufacturing and packaging in outsourcing and is now a reliable partner for nutritional supplements, nutraceutical, cosmetics and medical devices markets.
The company reached 83.4 million euros in revenues in 2014 (of which 63% realized in Italy and 37% abroad) with 12.3 millions of ebitda and 18 millions of net financial debt. The deal will be financed all by equity as Trilantic projects to support Doppel’s future bsuiness development both by organic growth and by acquisitions, Trilantic Capital europe’s founder and chairman Vittorio Pignatti Morano said in a press release last Friday July 24.
La Torre Morgese Cèsaro Rio law firm advised Trilantic as for the legal issues, financial advisor was Ethica Corporate Finance. The sellers were supported by d’Urso Gatti Pavesi Bianchi law firm.
